Featured Research

from universities, journals, and other organizations

Experimental Lymphoma Vaccine Tested At UCLA's Jonsson Cancer Center

Date:
July 19, 2001
Source:
University Of California - Los Angeles
Summary:
Researchers at UCLA’s Jonsson Cancer Center are seeking volunteers for a final phase clinical trial that will test the safety and effectiveness of individually tailored vaccines to fight a common type of lymphoma. The vaccines will be manufactured to target proteins unique to each patient’s lymphoma, said Dr. Christos Emmanouilides, director of the Clinical Lymphoma Research Program at the Jonsson Cancer Center and principal investigator for the multi-center study.

Researchers at UCLA’s Jonsson Cancer Center are seeking volunteers for a final phase clinical trial that will test the safety and effectiveness of individually tailored vaccines to fight a common type of lymphoma.

The vaccines will be manufactured to target proteins unique to each patient’s lymphoma, said Dr. Christos Emmanouilides, director of the Clinical Lymphoma Research Program at the Jonsson Cancer Center and principal investigator for the multi-center study.

UCLA’s Jonsson Cancer Center is the only institution in Southern California to offer this experimental vaccine therapy, researchers said.

The vaccine therapy, which will be combined with chemotherapy, has prompted encouraging results in earlier phase studies of about 100 people conducted at Stanford University, Emmanouilides said. To qualify for the study, volunteers should have untreated follicular lymphoma, a common form of cancer of the lymph nodes.

This type of lymphoma is considered incurable in most cases, Emmanouilides said. By the time it’s diagnosed, the cancer often has spread to many lymph node groups or other organs. It can be manageable, but a cure is rare. However, the vaccine may provide some hope, he said.

“This may give us a new system to fight it,” Emmanouilides said. “It’s an exciting concept.”

Volunteers for the study will have a sample of their cancerous tissue removed during a needle biopsy. That sample will be used to manufacture the vaccine. Volunteers will undergo eight rounds of chemotherapy and then will be injected with the individually tailored vaccine, which researchers hope will prompt the body’s immune system to fight off the cancer while leaving healthy cells alone. Volunteers must undergo five weekly injections of the vaccine.

The injections will be done at UCLA’s Jonsson Cancer Center. However, volunteers can get the chemotherapy at oncology offices in their own communities, Emmanouilides said.

In previous studies of the vaccine, patients remained in remission much longer than expected, Emmanouilides said. The Phase III randomized study — the last phase of testing before a drug is submitted for approval — is expected to last from one to two years.

Two-thirds of the study volunteers will receive chemotherapy and the individually manufactured vaccines. The remaining third will receive chemotherapy and a non-specific immune system stimulant, Emmanouilides said. All study volunteers will receive the chemotherapy regimen considered the conventional treatment for lymphoma, so treatment is not compromised.

In all, UCLA hopes to recruit more than 50 volunteers to participate in the study.

“This study will give us the opportunity to confirm the very encouraging Phase II results seen at Stanford,” Emmanouilides said. “And it will allow us to provide a very sophisticated treatment for our patients.”

Lymphoma is a cancer that starts in the lymphatic tissue. The lymphatic system serves an important bodily function, filtering germs and cancer cells as well as fluid from the extremities and internal organs. This tissue is found in many places throughout the body, including lymph nodes, the thymus, the spleen, the tonsils and adenoids, in the bone marrow, and scattered within other systems such as the digestive and respiratory tracts.

The American Cancer Society estimates that 63,600 new cases of lymphoma will be diagnosed this year. About 27,600 people will die from the disease.

###

For more information on the study, or to volunteer for the vaccine therapy, patients should call 310-825-2516 or 310-794-4376.

For more information about UCLA’s Jonsson Cancer Center, its people and resources, visit our Web site at http://www.cancer.mednet.ucla.edu.


Story Source:

The above story is based on materials provided by University Of California - Los Angeles. Note: Materials may be edited for content and length.


Cite This Page:

University Of California - Los Angeles. "Experimental Lymphoma Vaccine Tested At UCLA's Jonsson Cancer Center." ScienceDaily. ScienceDaily, 19 July 2001. <www.sciencedaily.com/releases/2001/07/010719080427.htm>.
University Of California - Los Angeles. (2001, July 19). Experimental Lymphoma Vaccine Tested At UCLA's Jonsson Cancer Center. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2001/07/010719080427.htm
University Of California - Los Angeles. "Experimental Lymphoma Vaccine Tested At UCLA's Jonsson Cancer Center." ScienceDaily. www.sciencedaily.com/releases/2001/07/010719080427.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins